Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

IASO IND for CAR-T to Treat Autoimmune Disease Accepted in China

publication date: May 31, 2022

Nanjing IASO Bio reported China accepted its IND for a BCMA CAR-T therapy, equecabtagene autoleucel, in patients with an autoimmune disease, Neuromyelitis Optica Spectrum Disorder (NMOSD). NMOSD is a demyelination disorder of the central nervous system that usually occurs in young and middle-aged people. IASO’s IND, which is one of the first for use of a CAR-T in inflammatory indications, is based on a China investigator-led test in NMOSD patients. The China acceptance is the world's first IND application for use of a CAR-T in NMOSD. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital